Next, we tested the effect of these two agents on FAS- and TNF-induced apoptosis in a panel of cell lines (HeLa, H1299 and A549, representing cervical adenocarcinoma, non-small cell lung carcinoma, and lung carcinoma cells, respectively) by pretreating the cells with inhibitors for 12 h before addition of FASL (HeLa) or TNF (HeLa, H1299, and A549) and then assessing cell viability 24 h later. The gene discussed is FAS; the disease is cervical adenocarcinoma.